BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

Leukemia

Volumn 29, Issue 9, 2015, Pages 1832-1838

  Hughes, T P ^a   Saglio, G ^b   Quintas Cardama A ^c   Mauro, M J ^d   Kim, D W ^e   Lipton, J H ^f   Bradley Garelik, M B ^g   Ukropec, J ^g   Hochhaus, A ^h  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e The Catholic University of Korea   (South Korea)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g BRISTOL MYERS SQUIBB   (United States)

^h JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SCREENING; CANCER THERAPY; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE; CHRONIC PATIENT; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PROGNOSIS; TIME; TREATMENT OUTCOME;

DASATINIB; DNA MUTATIONAL ANALYSIS; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MUTATION; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84940797444     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.168     Document Type: Article

References (61)

1. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006; 20: 1767-1773.
2. Parker WT, Lawrence RM, Ho M, Irwin DL, Scott HS, Hughes TP et al. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. J Clin Oncol 2011; 29: 4250-4259.
3. Müller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009; 114: 4944-4953.
4. Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009; 27: 4204-4210.
5. Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; 114: abstract 1126.
6. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
7. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-125.
8. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276-283.
9. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23: 4100-4109.
10. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358-3363.
11. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006; 12: 7374-7379.
12. Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011; 118: 1208-1215.
13. Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res 2014; 38: 10-20.
14. Cortes JE, Kantarjian HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011; 118: 4567-4576.
15. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369: 1783-1796.
16. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009; 27: 469-471.
17. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367: 2075-2088.
18. Bristol-Myers Squibb Company. Sprycel (dasatinib) [prescribing information]. Princeton, NJ, 2014.
19. Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) [prescribing information]. East Hanover, NJ, 2015.
20. European Medicines Agency. European public assessment reports for Sprycel. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000709/human-med-001062.jsp&murl =menus/medicines/medicines.jsp&mid = WC0b01ac058001d125 (last accessed 5 February 2015).
21. European Medicines Agency. European public assessment reports for Tasigna. http:// www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000798/ human-med-001079.jsp&mid=WC0b01ac058001d124 (last accessed 5 February 2015).
22. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197-2203.
23. Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014; 123: 494-500.
24. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119: 1123-1129.
25. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841-851.
26. [published erratum appears in Lancet Oncol 2011; 12: 989].
27. Hochhaus A, Saglio G, Larson RA, Kim DW, Etienne G, Rosti G et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2013; 121: 3703-3708.
28. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
29. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-1820.
30. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37.
31. Müller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957-1963.
32. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872-884.
33. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500-4505.
34. Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108: 2332-2338.
35. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S et al. Dynamics of BCRABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007; 110: 4005-4011.
36. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007; 117: 2562-2569.
37. Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second-or third-line tyrosine kinase inhibitors. Blood 2009; 114: 2168-2171.
38. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 2008; 112: 4839-4842.
39. Khorashad JS, Milojkovic D, Mehta P, Anand M, Ghorashian S, Reid AG et al. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 2008; 111: 2378-2381.
40. Quintás-Cardama A, Kantarjian H, Shah NP, Schiffer CA, le Coutre P, Saglio G et al. Patients with chronic myeloid leukemia in chronic phase carrying more than one BCR-ABL kinase domain mutation exhibit poorer response rates and outcomes to second-line dasatinib compared to those with no or only one BCR-ABL mutation. Blood 2010; 116: abstract 2297.
41. Parker WT, Ho M, Scott HS, Hughes TP, Branford S. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood 2012; 119: 2234-2238.
42. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-2541.
43. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018-1029.
44. Nicolini FE, Corm S, Lê QH, Roche-Listienne C, Preudhomme C. The prognosis impact of BCR-ABL P-loop mutations: worse or not worse? Leukemia 2007; 21: 193-194.
45. ClinicalTrials.gov: A service of the U.S. National Institutes of Health. Study of dasatinib in patients with chronic myelogenous leukemia. http://clinicaltrials.gov/ show/NCT00254423 (last accessed 1 October 2014).
46. ClinicalTrials.gov: A service of the U.S. National Institutes of Health. Imatinib mesylate or dasatinib in treating patients with chronic phase chronic myelogenous leukemia. http://clinicaltrials.gov/show/NCT00070499 (last accessed 1 October 2014).
47. Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006; 26: 6082-6093.
48. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 2009; 114: 5426-5435.
49. Ernst T, Erben P, Müller MC, Paschka P, Schenk T, Hoffmann J et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008; 93: 186-192.
50. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C et al. Long-term outcome of patients with chronic myeloid leukemia treated with secondgeneration tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009; 114: 2037-2043.
51. Kim WS, Kim D, Kim DW, Kweon IY, Kim SH, Goh HG et al. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors. Hematol Oncol 2010; 28: 82-88.
52. Ahn JS, Kim YK, Lee SR, Yu L, Yang DH, Cho SH et al. Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity. Cancer Res Treat 2010; 42: 37-41.
53. Branford S, Hochhaus A, Mueller M, Bahceci E, Ploughman L, Mukhopadhyay J et al. Analysis of molecular data and the emergence of mutations for chronicphase chronic myelogenous leukemia (CML-CP) patients treated with dasatinib after imatinib failure. Blood 2009; 114: abstract 3282.
54. Gruber FX, Ernst T, Porkka K, Engh RA, Mikkola I, Maier J et al. Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients. Leukemia 2012; 26: 172-177.
55. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology-Chronic Myelogenous Leukemia v1.2015. http://www.nccn.org/pro fessionals/physician-gls/f-guidelines.asp (last accessed 1 October 2014).
56. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401-412.
57. Jabbour EJ, Makenbaeva D, Lingohr-Smith M, Lin J. Potential economic consequences of genetic mutations and restricted acccess to tyrosine kinase inhibitor treatments among patients with chronic myelogenous leukemia in the USA. Blood 2014; 124: abstract 2645.
58. Iqbal Z, Aleem A, Iqbal M, Naqvi MI, Gill A, Taj AS et al. Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. PLoS One 2013; 8: e55717.
59. Lange T, Ernst T, Gruber FX, Maier J, Cross M, Müller MC et al. The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to secondline nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica 2013; 98: 714-717.
60. Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128-2137.
61. Jiang X, Forrest D, Nicolini F, Turhan A, Guilhot J, Yip C et al. Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood 2010; 116: 2112-2121.